Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Amanda J Redig

Showing results (31-40 of 45) with videos related to

Pageof 5
Sort By:
The Journal of Biological Chemistry|December 1, 2007
Regulatory effects of mammalian target of rapamycin-mediated signals in the generation of arsenic trioxide responsesJessica K Altman, Patrick Yoon, Efstratios Katsoulidis, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 4, 2009
Type I interferon (IFN)-dependent activation of Mnk1 and its role in the generation of growth inhibitory responsesSonali Joshi, Surinder Kaur, Amanda J Redig, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 10, 2016
A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non-Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II TrialMasahiko Yanagita, Amanda J Redig, Cloud P Paweletz, et al.
Cancer Research|April 2, 2017
Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 InhibitorsTakayuki Kosaka, Junko Tanizaki, Raymond M Paranal, et al.
Cancer Cell|April 4, 2020
A Deregulated HOX Gene Axis Confers an Epigenetic Vulnerability in KRAS-Mutant Lung CancersStephanie L Guerra, Ophélia Maertens, Ryan Kuzmickas, et al.
JAMA Oncology|August 4, 2018
Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M-Positive Lung Cancer and Acquired Resistance to OsimertinibGeoffrey R Oxnard, Yuebi Hu, Kathryn F Mileham, et al.
Neuro-Oncology|April 27, 2017
Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based studyDaniel N Cagney, Allison M Martin, Paul J Catalano, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|February 6, 2018
Impact of pemetrexed on intracranial disease control and radiation necrosis in patients with brain metastases from non-small cell lung cancer receiving stereotactic radiationDaniel N Cagney, Allison M Martin, Paul J Catalano, et al.
Elife|November 1, 2017
Correction: KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancerElsa Beyer Krall, Belinda Wang, Diana M Munoz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 29, 2022
Comparative Analysis and Isoform-Specific Therapeutic Vulnerabilities of KRAS Mutations in Non-Small Cell Lung CancerBiagio Ricciuti, Jieun Son, Jeffrey J Okoro, et al.
Pageof 5

Showing results (31-40 of 45) with videos related to

Sort By:
Pageof 5
The Journal of Biological Chemistry|December 1, 2007
Regulatory effects of mammalian target of rapamycin-mediated signals in the generation of arsenic trioxide responsesJessica K Altman, Patrick Yoon, Efstratios Katsoulidis, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 4, 2009
Type I interferon (IFN)-dependent activation of Mnk1 and its role in the generation of growth inhibitory responsesSonali Joshi, Surinder Kaur, Amanda J Redig, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 10, 2016
A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non-Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II TrialMasahiko Yanagita, Amanda J Redig, Cloud P Paweletz, et al.
Cancer Research|April 2, 2017
Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 InhibitorsTakayuki Kosaka, Junko Tanizaki, Raymond M Paranal, et al.
Cancer Cell|April 4, 2020
A Deregulated HOX Gene Axis Confers an Epigenetic Vulnerability in KRAS-Mutant Lung CancersStephanie L Guerra, Ophélia Maertens, Ryan Kuzmickas, et al.
JAMA Oncology|August 4, 2018
Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M-Positive Lung Cancer and Acquired Resistance to OsimertinibGeoffrey R Oxnard, Yuebi Hu, Kathryn F Mileham, et al.
Neuro-Oncology|April 27, 2017
Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based studyDaniel N Cagney, Allison M Martin, Paul J Catalano, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|February 6, 2018
Impact of pemetrexed on intracranial disease control and radiation necrosis in patients with brain metastases from non-small cell lung cancer receiving stereotactic radiationDaniel N Cagney, Allison M Martin, Paul J Catalano, et al.
Elife|November 1, 2017
Correction: KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancerElsa Beyer Krall, Belinda Wang, Diana M Munoz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 29, 2022
Comparative Analysis and Isoform-Specific Therapeutic Vulnerabilities of KRAS Mutations in Non-Small Cell Lung CancerBiagio Ricciuti, Jieun Son, Jeffrey J Okoro, et al.
Pageof 5